Want to see KIDS full AI Analyst Report?
KIDS Stock Chart & Stats
$18.87
$0.95(5.03%)
At close: 4:00 PM EDT
$18.87
$0.95(5.03%)
Day’s Range― - ―
52-Week Range$14.42 - $22.80
Previous Close$20.42
Volume117.04K
Average Volume (3M)196.93K
Market Cap
$518.58M
Enterprise Value$431.30
Total Cash (Recent Filing)$45.88M
Total Debt (Recent Filing)$91.59M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding25,684,994
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.88Price Target Upside42.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$265.24M
Bulls Say, Bears Say
Bulls Say
Very High, Stable Gross MarginsSustained gross margins near the mid-70s provide a durable structural advantage, enabling scalable profit leverage as revenue grows. High margins reflect product differentiation and favorable mix (new higher-ASP launches), supporting long-term margin sustainability even as SG&A scales.
Niche Market Leadership & Large Addressable MarketA pediatric-only focus and exclusive pediatric sales network create a meaningful competitive moat versus adult-focused incumbents. Deep clinical relationships and coverage of top children’s hospitals support durable adoption, multi-year product penetration, and sustained revenue expansion.
Improving Profitability Trajectory & Cash OutlookManagement’s raised guidance, record adjusted EBITDA and explicit H2 free-cash-flow positivity signal a credible path to self-funding. Sustained improvement in operating results reduces refinancing risk and supports disciplined capital allocation over the medium term.
Bears Say
Persistent Operating LossesDespite strong top-line growth and high gross margins, recurring operating and net losses limit return on invested capital and equity quality. Continued losses constrain reinvestment flexibility and shareholder value creation until underlying operating profitability is consistently achieved.
Free Cash Flow Remains Negative TTMNegative free cash flow indicates reinvestment and capex are outpacing internal cash generation, maintaining reliance on the balance sheet or external funding. This structural funding gap raises risk if operating improvements stall or capex requirements persist.
Revenue/cash Timing And International Execution RiskCapital-equipment timing, distributor stocking and deliberate deployment discipline create lumpy revenue and cash conversion. International execution variability (e.g., Brazil) and timing-sensitive set sales can materially affect quarterly results and cash flow over multiple quarters.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $22.80 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $518.58M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Nov 03, 2026 which is in 89 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.002.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.23.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 25,684,994 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.88 (42.42% Upside)
$26.88 (42.42% Upside)
Blogger Sentiment
Bullish
KIDS Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 254.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$26.88
▲(42.42% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―
Ownership Overview
33.38% Insiders
13.08% Mutual Funds
3.60% Other Institutional Investors
42.11% Public Companies and
Individual Investors